KRAS and lung carcinoma: However, in a pooled analysis from the German National Network Genomic Medicine Lung Cancer, which evaluated first-line treatment outcomes with pembrolizumab in non-squamous PD-L1 ≥ 50% patients according to KRAS/TP53 mutational status, it was noted that G12C/TP53-mutated patients experienced the longest PFS and OS (33.7 and 65.3 months, respectively; p = 0.002).